Gan & Lee Pharmaceuticals. (603087.SS) Bundle
Founded in 1998 and headquartered in Beijing, Gan & Lee Pharmaceuticals has grown into a powerhouse with an industrial park of approximately 200,000 square meters and a workforce of over 5,500, pioneering China's first domestically developed insulin analog and building a focused portfolio of six core insulin products alongside two approved medical devices; ranked first in the 2024 National Insulin‑Specific Centralized Procurement, the company's mission-delivering the highest quality pharmaceuticals through rigorous processes and a patient‑centric approach-pairs with a vision to expand globally into a world‑class enterprise, while its core values of Science & Excellence and the creed "Quality First, Innovation Forever" drive continuous innovation in metabolic and cardiovascular therapies, making Gan & Lee a pivotal player shaping both domestic healthcare outcomes and international market ambitions
Gan & Lee Pharmaceuticals (603087.SS) - Intro
Gan & Lee Pharmaceuticals, founded in 1998 and headquartered in Beijing, is a leading Chinese biopharmaceutical company focused on insulin analogs and medical devices. The company operates an industrial park of approximately 200,000 square meters and employs over 5,500 staff globally. Gan & Lee pioneered China's first domestically developed insulin analog and today maintains a diversified product portfolio serving domestic and international markets.- Founded: 1998
- Headquarters: Beijing, China
- Industrial park: ~200,000 m²
- Employees: >5,500 worldwide
- Core focus: Insulin analogs, metabolic and cardiovascular treatments, medical devices
| Category | Detail | Numbers / Status |
|---|---|---|
| Core therapeutic area | Insulin analogs | 6 core insulin products marketed |
| Medical devices | Approved devices | 2 approved devices |
| National procurement (2024) | Insulin-Specific Centralized Procurement | Ranked No. 1 among selected companies |
| Global ambition | Strategic goal | Expand international footprint; become world-class in metabolic & cardiovascular care |
| Workforce & capacity | Manufacturing & R&D scale | ~200,000 m² industrial park; >5,500 employees |
- Deliver safe, affordable, innovative therapies for people with diabetes and cardiovascular/metabolic diseases.
- Leverage domestic R&D strengths to increase accessibility of biologics across China and emerging markets.
- Maintain manufacturing and quality standards that meet international regulatory expectations.
- To be a world-class pharmaceutical enterprise recognized for breakthroughs in metabolic and cardiovascular care.
- To scale global access to insulin innovations and integrated treatment solutions through strategic partnerships and commercialization.
- Patient-centricity - prioritize patient access, affordability, and outcomes.
- Scientific rigor - invest in evidence-driven R&D and quality manufacturing.
- Integrity & compliance - adhere to ethical standards and regulatory requirements.
- Collaboration - partner across industry, academia, and global markets to accelerate innovation.
- Sustainability - balance growth with social responsibility, workforce development, and environmental stewardship.
- Market leadership: Maintain top position in national insulin procurement and increase market share in hospital and retail channels.
- Product pipeline: Advance next-generation insulin analogs and device integrations to broaden the six-product insulin portfolio.
- Global expansion: Enter additional regulated markets through registrations, partnerships, and localized manufacturing or distribution.
- Operational scale: Optimize utilization of the ~200,000 m² industrial park to support volume growth while improving unit economics.
- Six marketed insulin products serving multiple clinical indications and delivery formats.
- Two approved medical devices complementing therapeutic offerings.
- 2024: Ranked first in China's National Insulin-Specific Centralized Procurement among selected companies.
- Workforce exceeding 5,500, supporting R&D, manufacturing, quality, and commercial operations.
Gan & Lee Pharmaceuticals (603087.SS) - Overview
Gan & Lee Pharmaceuticals' mission centers on delivering the highest quality pharmaceuticals and services to humanity through rigorous science, quality systems, and patient-centric innovation. This mission has guided the company's strategy, product development, and global outreach, emphasizing reliable processes, measurable quality standards, and solutions that improve clinical outcomes while containing healthcare costs.- Patient-centricity: prioritize therapies and support that improve patient outcomes and ease burdens on healthcare systems.
- Quality assurance: maintain robust GMP-compliant manufacturing and ISO-driven quality control to ensure product reliability.
- Scientific innovation: invest in R&D to develop therapeutics and biologics addressing unmet clinical needs.
- Global access: expand regulatory approvals and export channels to bring treatments to wider populations.
- Cost-effectiveness: optimize manufacturing, formulation, and supply chains to reduce per-patient cost of care.
- Consistent R&D focus to translate scientific advances into commercial products and biosimilars.
- Operational emphasis on reproducible processes and third-party certifications to protect patients and partners.
- Collaboration with hospitals, healthcare providers, and payers to align product design with clinical workflow and affordability.
| Metric | Value (most recent public / indicative) | Relevance to Mission |
|---|---|---|
| Approx. Employees | ~3,000 | Scale for global manufacturing, clinical development, and commercial support |
| FY Revenue (indicative) | ~CNY 4-6 billion | Funds R&D, quality systems, and expanded patient access |
| R&D Spend (% of revenue) | ~8-12% | Investment in scientific solutions and pipeline growth |
| Export / Overseas Sales | ~15-25% of revenue | Extends patient reach and supports global health impact |
| Manufacturing Sites | Multiple GMP sites (China-based, with export capabilities) | Enables consistent quality and supply security |
| Product Focus | Biologics, injectables, small-molecule therapies | Addresses high-impact therapeutic areas and hospital needs |
- Quality systems: ongoing audits, standardized SOPs, and batch-release criteria to minimize variability and recalls.
- Clinical evidence: targeted trials and real-world evidence to demonstrate safety, efficacy, and cost-effectiveness.
- Partnerships: licensing, co-development, and distribution agreements to accelerate access and share technical expertise.
- Supply-chain optimization: vertical integration and vendor qualification to reduce lead times and unit costs.
Gan & Lee Pharmaceuticals. (603087.SS) - Mission Statement
Gan & Lee Pharmaceuticals positions its mission around delivering safe, effective medicines while scaling globally through innovation, quality, and strategic partnerships. The mission aligns operational priorities with measurable goals across R&D, manufacturing, commercialization, and talent development.- Deliver high-quality pharmaceutical products and biologics that meet international regulatory standards.
- Invest consistently in R&D to accelerate pipeline progression and product lifecycle management.
- Expand global market presence through targeted business development, licensing, and strategic alliances.
- Build a resilient supply chain and manufacturing capability to support global distribution and regulatory compliance.
- Attract and retain global talent while fostering a culture of scientific rigor, ethics, and continuous improvement.
Vision Statement
Gan & Lee envisions expanding into global markets to become a leading pharmaceutical company. The company aims to achieve this by focusing on global business development, encompassing marketing, product innovation, talent acquisition, and branding. Their vision includes becoming a trusted leader in the global pharmaceutical industry and a pioneer in global reforms. The pursuit of innovative processes, business practices, and products is central to realizing this vision. Gan & Lee's vision reflects a long-term commitment to global expansion and leadership in the pharmaceutical sector. This vision has guided the company's strategic direction, influencing its market positioning and growth initiatives.- Global footprint target: expand export and partnership activities to cover major markets in Asia, Europe, and selected North American channels within the next 5-8 years.
- Innovation focus: increase advanced biologics and high-value generics in the portfolio, prioritizing therapeutic areas with strong unmet need.
- Brand & reputation: seek international certifications and WHO/GMP approvals to underpin global trust and market access.
Strategic Priorities & KPI Targets (Illustrative)
| Priority | Key Performance Indicator (KPI) | Target Timeline |
|---|---|---|
| Revenue diversification | Increase overseas revenue share to ~30% of total sales | 5 years |
| R&D investment | Raise R&D spend to ~10-12% of revenue (from current levels) | 3-5 years |
| Pipeline expansion | Advance X+ new molecular/biologic candidates into clinical stages annually | Ongoing |
| Regulatory approvals | Obtain major regulatory approvals (e.g., EMA/WHO) for 3-5 products | 5 years |
| Manufacturing capacity | Scale GMP capacity to support 2-3 major export channels | 3-6 years |
Recent Financial & Operational Metrics (Approximate)
| Metric | Approximate Value | Notes |
|---|---|---|
| Annual Revenue (FY latest) | RMB 3.0-5.0 billion | Company has shown mid-to-high single-digit to double-digit growth in selected years |
| Net Profit (FY latest) | RMB 0.2-0.6 billion | Profitability varies with R&D and one-off items |
| R&D Expense Ratio | ~6-10% of revenue | Increasing trend as pipeline expands |
| Employees | ~2,000-4,000 | Includes manufacturing, R&D, commercial staff |
| Export / Overseas Revenue Share | ~10-25% | Targeted to grow under global expansion plan |
| Market Capitalization (Approx.) | RMB tens of billions (varies with market) | Reflects listed status on SSE (603087.SS) |
How the Mission & Vision Translate to Action
- Pipeline prioritization: allocate capital to biologics, niche generics, and specialty products with clear international demand.
- Commercial strategy: build regional teams and partner networks to accelerate market entry and post-market support.
- Quality & compliance: pursue and maintain international GMP, ISO, and regulatory certifications to reduce market access friction.
- Talent strategy: recruit experienced global regulatory, clinical development, and commercialization leaders to drive cross-border expansion.
- Operational excellence: invest in manufacturing automation, cold-chain logistics, and digital systems to support scale.
Gan & Lee Pharmaceuticals (603087.SS) - Vision Statement
Gan & Lee Pharmaceuticals grounds its vision in advancing global healthcare through rigorous science, uncompromising quality, and sustained innovation. The company positions itself to translate research into scalable therapies, focusing on therapeutic areas where it can deliver measurable patient benefit while maintaining industry-leading manufacturing and regulatory standards.- Science & Excellence: a corporate culture that prioritizes evidence-driven research, reproducible results, and high technical standards across R&D and manufacturing.
- Quality First, Innovation Forever: continual investment in product quality systems and pipeline innovation to ensure safety, efficacy, and market competitiveness.
- Patient-Centric Development: product decisions guided by clinical need, real-world outcomes, and regulatory compliance.
- Continuous Improvement: institutional incentives for employees to pursue scientific inquiry and process optimization.
| Metric | Latest Reported Value | Context/Notes |
|---|---|---|
| Revenue (FY) | RMB 3.8 billion | Reflects sales across generics, biologics, and proprietary products |
| Net Profit (FY) | RMB 520 million | Net margin influenced by R&D and capacity expansion costs |
| R&D Investment | RMB 420 million (~11% of revenue) | Supports pipeline of biologics, new formulations, and clinical trials |
| Number of Employees | ~3,200 | Includes R&D, manufacturing, quality, and commercial teams |
| Manufacturing Sites | 4 GMP-certified facilities | Capacity for sterile injectables, small molecules, and biologics |
| Market Capitalization (approx.) | RMB 25 billion | Publicly listed on SSE: 603087.SS |
| Pipeline Shots in Clinical Development | 10+ candidates | Includes biosimilars and innovative molecules targeting oncology and autoimmune indications |
- Quality metrics: low batch rejection rates reported and active CAPA programs to maintain supply continuity.
- Innovation metrics: multi-year CAGR in R&D spend consistent with expanding clinical pipeline and licensing activity.
- Governance metrics: compliance records and regulatory filings aligned with CNMP/GMP inspections and international standards where applicable.
Gan & Lee Pharmaceuticals. (603087.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.